4.Inflammatory tinea capitis: non-healing plaque on the occiput of a 4-year-old child.
Chia Chun ANG ; Yong Kwang TAY
Annals of the Academy of Medicine, Singapore 2010;39(5):412-414
INTRODUCTIONInflammatory tinea capitis is an uncommon condition in Singapore. In this case report we present a patient whom we managed for this condition.
CLINICAL PICTUREA 4-year-old girl presented to us with multiple pustules over the occipital scalp for 6 weeks, associated with painful cervical lymphadenopathy. Her condition did not respond to topical and oral antibiotics.
TREATMENTThe patient was diagnosed with kerion (inflammatory tinea capitis) and fungal culture of plucked hairs from the kerion grew Microsporum species of dermatophyte. She was treated with a course of oral griseofulvin and topical selenium sulfide shampoo. She was advised to bring her pet cats to the veterinarian for screening, as well as not to share combs with her other siblings.
OUTCOMEHer condition improved with the antifungal therapy, and there was no residual alopecia.
CONCLUSIONPhysicians should consider tinea capitis when they encounter a patient with scalp folliculitis or scarring alopecia in the appropriate clinical context.
Administration, Oral ; Administration, Topical ; Antifungal Agents ; administration & dosage ; Child, Preschool ; Female ; Griseofulvin ; administration & dosage ; Humans ; Microsporum ; isolation & purification ; Selenium Compounds ; administration & dosage ; Tinea Capitis ; drug therapy ; microbiology
5.Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
Ling Zhi HENG ; Yujia CHEN ; Thiam Chye TAN
Singapore medical journal 2012;53(12):e269-71
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
Adult
;
Antifungal Agents
;
administration & dosage
;
Candidiasis, Vulvovaginal
;
drug therapy
;
Female
;
Humans
;
Imidazoles
;
administration & dosage
;
Middle Aged
;
Pessaries
;
Recurrence
6.Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis.
Jiang Ying YAN ; Xiao Lu NIE ; Qing Mei TAO ; Si Yan ZHAN ; Yan De ZHANG
Biomedical and Environmental Sciences 2013;26(7):605-610
OBJECTIVETo evaluate the incidence of Ketoconazole associated hepatotoxicity and related factor.
METHODSLiterature retrieval was conducted by using multi-databases for meta-analysis on Ketoconazole associated hepatotoxicity. The data were collected with a standardized form. Overall estimation of incidence of hepatotoxicity for specific study type was calculated by using a DerSimonian-Laird random-effects model owing to the substantial differences among the studies.
RESULTSTotally 204 eligible studies were included in the analysis. The incidence of Ketoconazole associated hepatotoxicity was 3.6%-4.2%. The dosage and duration specific subgroup analyses did not show any significant difference among groups, while the age specific subgroup analysis showed the incidence in children and people aged >60 years was 1.4% (95% CI: 0.5%-4.2%) and 3.2% (95% CI: 1.1%-8.7%) respectively. Additionally, the incidence of the hepatotoxicity was higher in people who had oral administration of ketoconazole beyond the provisions of the usage instructions, and the incidence was 5.7% (95% CI: 4.5%-7.2%).
CONCLUSIONKetoconazole associated hepatotoxicity was common. Off-label use might increase the risk of liver damage. Well-designed large sample studies are needed to identify the risk factors in future.
Antifungal Agents ; administration & dosage ; adverse effects ; Chemical and Drug Induced Liver Injury ; etiology ; Humans ; Ketoconazole ; administration & dosage ; adverse effects ; Off-Label Use
7.Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report.
Zhang YAO ; Zhang HUA ; Xu JUN ; Wu CHAN ; Ma XIAO-JUN
Chinese Medical Sciences Journal 2011;26(4):246-248
Pneumocystis pneumonia (PCP) is among the most common opportunistic infections in patients with acquired immune deficiency syndrome (AIDS). Although trimethoprim-sulfamethoxazole (TMP-SMX) is the first line therapy for that condition given its efficacy, approximately one third of patients experienced dose-limiting toxicity. For cases of severe to moderate PCP, if TMP-SMX treatment fails or is contraindicated, primaquine combined with clindamycin or intravenous pentamidine is recommended as second line therapy. However, both primaquine and pentamidine are associated with severe adverse reactions and often unavailable at hospitals in China.As a result, other treatment options have been explored. Caspofungin, an echinocandin, has broad antifungal activity against a wide range of fungi including Candida and Aspergillus species. Cases of PCP patients treated with caspofungin have been reported, although conflicting conclusions have been arrived at. In addition, the use of caspofungin and clindamycin as the first line therapy for severe PCP in AIDS patients has not been reported yet. This article described an AIDS case with severe PCP, treated with the combination of caspofungin and clindamycin.
AIDS-Related Opportunistic Infections
;
drug therapy
;
Adult
;
Anti-Bacterial Agents
;
administration & dosage
;
Antifungal Agents
;
administration & dosage
;
Clindamycin
;
administration & dosage
;
Drug Therapy, Combination
;
Echinocandins
;
administration & dosage
;
Humans
;
Lipopeptides
;
Male
;
Pneumonia, Pneumocystis
;
drug therapy
8.Two Cases of Disseminated Mucormycosis in Patients following Allogeneic Bone Marrow Transplantation.
Dong Gun LEE ; Jung Hyun CHOI ; Su Mi CHOI ; Jin Hong YOO ; Yoo Jin KIM ; Chang Ki MIN ; Seok LEE ; Dong Wook KIM ; Wan Shik SHIN ; Chun Choo KIM
Journal of Korean Medical Science 2002;17(3):403-406
We describe two cases of disseminated mucormycosis following allogeneic bone marrow transplantation (BMT). Both patients were suffering from chronic graft-ver-sus-host disease (GVHD) and treated with prolonged administration of corticosteroid. In both cases, the initial symptoms were high fever and left flank pain. Involved organs were the spleen, right kidney and the right lung in one case, and the spleen and the brain in the other. The diagnosis was confirmed by pathology after splenectomy. One patient, in whom the immunosuppressesants could be discontinued, was treated with prolonged conventional and liposomal amphotericin B and 5-fluorocytosine. The other, in whom the immunosuppressants could not be discontinued due to extensive GVHD, was unresponsive to amphotericin B, and eventually died from the fungal infection. Although mucormycosis, especially the disseminated form thereof is infrequent, it should be considered in high-risk patients because early diagnosis and timely therapy combining antifungal drug or surgery and reduction of immunosuppression appear to improve the prognosis.
Adult
;
Amphotericin B/administration & dosage
;
Antifungal Agents/administration & dosage
;
*Bone Marrow Transplantation
;
Fatal Outcome
;
Humans
;
*Immunocompromised Host
;
Immunosuppressive Agents/administration & dosage
;
Male
;
Mucormycosis/drug therapy/immunology/*pathology
;
Transplantation, Homologous
9.Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea.
Dong Gun LEE ; Sung Han KIM ; Soo Young KIM ; Chung Jong KIM ; Wan Beom PARK ; Young Goo SONG ; Jung Hyun CHOI
The Korean Journal of Internal Medicine 2011;26(2):220-252
Neutrophils play an important role in immunological function. Neutropenic patients are vulnerable to infection, and except fever is present, inflammatory reactions are scarce in many cases. Additionally, because infections can worsen rapidly, early evaluation and treatments are especially important in febrile neutropenic patients. In cases in which febrile neutropenia is anticipated due to anticancer chemotherapy, antibiotic prophylaxis can be used, based on the risk of infection. Antifungal prophylaxis may also be considered if long-term neutropenia or mucosal damage is expected. When fever is observed in patients suspected to have neutropenia, an adequate physical examination and blood and sputum cultures should be performed. Initial antibiotics should be chosen by considering the risk of complications following the infection; if the risk is low, oral antibiotics can be used. For initial intravenous antibiotics, monotherapy with a broad-spectrum antibiotic or combination therapy with two antibiotics is recommended. At 3-5 days after beginning the initial antibiotic therapy, the condition of the patient is assessed again to determine whether the fever has subsided or symptoms have worsened. If the patient's condition has improved, intravenous antibiotics can be replaced with oral antibiotics; if the condition has deteriorated, a change of antibiotics or addition of antifungal agents should be considered. If the causative microorganism is identified, initial antimicrobial or antifungal agents should be changed accordingly. When the cause is not detected, the initial agents should continue to be used until the neutrophil count recovers.
Anti-Bacterial Agents/*administration & dosage
;
Antibiotic Prophylaxis/*standards
;
Antifungal Agents/*administration & dosage
;
Drug Administration Schedule
;
Evidence-Based Medicine
;
Fever/diagnosis/*drug therapy/etiology
;
Humans
;
Neutropenia/diagnosis/*drug therapy/etiology
;
Republic of Korea
;
Time Factors
;
Treatment Outcome
10.Clinical observation on treatment of mycotic vaginitis with Sophora gel combined with Fluconazole capsules.
Na-mei WANG ; Lin CUI ; Chun-fen MA ; Hui-xia WANG
China Journal of Chinese Materia Medica 2015;40(5):978-980
Mycotic vaginitis is a common and frequently-occurring gynaecopathia and easy to attack repeatedly, so painful to patients. In this study, the authors observed the clinical efficacy of Sophora gel combined with Fluconazole capsules in treating mycotic vaginitis, in order to seek an effective method for treating mycotic vaginitis. Totally 85 patients with mycotic vaginitis treated in our hospital between December 2012 and July 2014 were randomly divided into the treatment group (43 patients) and the control group (42 patients). The treatment group was given vaginally Sophora gel (one piece every night for 14 days) and orally Fluconazole capsules (150 mg, once every three days, four times in total); The control group was only administered with Fluconazole capsules. The total efficacy, cure rate, recurrence rate and clinical symptom improvements of the two groups were observed. The results show that the total efficacy, the cure rate and the recurrence rate of the treatment group vs. the control group were respectively 97.7%, 90.7% and 2.6% vs. 83.3%, 71.4% and 20.0%, with statistical significance in their differences (P < 0.05). The treatment group showed reduced leucorrhea, pruritus vulvae disappearance and earlier mucosal hyperemia disappearance than the control group, with statistical significance in their differences (P < 0.05). In conclusion Sophora gel combined with Fluconazole capsules can improve antifungal activity of drugs, relieve clinical symptoms, shorten the course of disease, enhance the cure rate and reduce the recurrence rate; So this therapy can be widely applied in clinic.
Adult
;
Antifungal Agents
;
administration & dosage
;
Capsules
;
administration & dosage
;
Drug Therapy, Combination
;
Drugs, Chinese Herbal
;
administration & dosage
;
Female
;
Fluconazole
;
administration & dosage
;
Humans
;
Mycoses
;
drug therapy
;
Sophora
;
chemistry
;
Treatment Outcome
;
Vaginitis
;
drug therapy
;
Young Adult